and regulate the functions of IGFs 44, 56 by modulating the bioavailability of IGFs and regulating tumor growth and invasion. 55, 56 IGFBP-3, with a molecular weight of 43-45 kD, is the most abundant of the IGFBPs in the circulation. It serves as a carrier for the IGFs and also directly modulates the actions of IGF-1 and -2 in tissues. 3, 45 It is a primary transport protein and thus can both enhance and inhibit IGF-1 actions. Furthermore, it has been shown to exhibit effects on proliferation, migration, and apoptosis that are independent of IGF signaling. 7, 40 Presumably, these multifunctional roles for IGFBP-3 are influenced by posttranslational modifications and susceptibility to proteases. 8, 13, 23, 33 In addition to IGF-I, several other molecules such as interleukin-1, tumor necrosis factor-a, transforming growth factor-b (TGFb), retinoic acid, as well as the PI3K/AKT and MAPK/ERK1/2 pathways have been implicated in the regulation of IGFBP-3 expression. 12, 40, 48 The overexpression of some IGFBP isoforms has been well documented in gliomas, in particular, glioblastoma (GBM). 15, 16, 32, 43, 46 A previous study by our group identified IGFBP-3 as a novel biomarker associated with an adverse GBM prognosis. 46 Additionally, IGFBP-3 has been recognized as a hypoxia-induced gene in a study on a malignant glioma cell line (U251). 41 IGFBP-3 has also been shown to be overexpressed in several other human cancers, such as melanoma, renal cell carcinoma, and breast and esophageal cancers, suggesting its plausible role in malignancy and progression.
6,21,52,59
Earlier studies have shown that IGFBP-3 modulates epidermal growth factor receptor and TGFb signaling pathways, suggesting a role in the pathogenesis of some human cancers. 34, 37, 52 Interestingly, IGFBP-3 has been shown to regulate signal transducer and activator of transcription 1 (STAT-1) expression during chondrogenesis. 49 The STAT proteins were identified primarily as signaling molecules implicated in interferon (IFN)-dependent cellular responses. 9, 51 In addition to its well-known function in immune surveillance, STAT-1 expression has also been shown to play an important role in tumor pathology. 31 So far, there is limited understanding of the biological and mechanistic functions of IGFBP-3 in gliomas. Since our previous study revealed that IGFBP-3 is a novel prognostic biomarker in GBM, in the present study we evaluated the mechanisms of tumor promotion by IGFBP-3 in glioma. We show that IGFBP-3 exerts its protumorigenic actions by regulating cell growth, migration, and invasion. Further, we show STAT-1 regulation by IGFBP-3 in malignant glioma cells, overexpression of STAT-1 in GBM tissue samples, and the association of STAT-1 expression with a poor prognosis in patients with GBM.
Methods
This study was approved by the ethics committees of the National Institute of Mental Health and Neurosciences and the Sri Sathya Sai Institute of Higher Medical Sciences. Fetal bovine serum (FBS), penicillin-streptomycin, and Lipofectamine-2000 were purchased from Invitrogen Life Technologies; Dulbecco's modified Eagle's medium (DMEM), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and puromycin, from Sigma-Aldrich; dimethyl sulfoxide, from Merck; 29-mer short hairpin (sh)RNA cassette directed against IGFBP-3 and scrambled shRNA (pRFP-C-RS shRNA vector), from OriGene Technologies Inc.; rabbit anti-IGFBP-3 polyclonal antibody, from Santa Cruz Biotechnology; mouse monoclonal anti-b-actin antibody (clone AC-15), anti-rabbit horseradish peroxidase (HRP) secondary antibody, anti-mouse HRP secondary antibody, from Sigma-Aldrich; SuperSignal West Femto Maximum Sensitivity Substrate, from Pierce; Cell Invasion Assay kit, from Chemicon; recombinant (r)IGFBP-3 protein, from Upstate Cell Signaling Solutions; and STAT-1 rabbit monoclonal antibody (clone 42H3), from Cell Signaling Technology.
Patients and Tissue Samples
Nontumor brain tissue samples (controls, n = 30) consisted of a portion of the anterior temporal cortex resected from patients who had undergone surgery for intractable epilepsy. Samples of GBM (n = 136) were obtained from patients who had undergone surgery at two clinical centers (National Institute of Mental Health and Neurosciences and Sri Sathya Sai Institute of Higher Medical Sciences, Bangalore, India). These patients were adults with newly diagnosed GBM who had been prospectively recruited and treated with standard radiochemotherapy. They had undergone macroscopic total or near-total resection of tumor, as confirmed on postoperative MRI, and had a postoperative Karnofsky Performance Scale (KPS) score ≥ 70. They had been subjected to uniform treatment, which included radiotherapy (total dose 59.4 Gy), along with concomitant chemotherapy with temozolomide (100 mg/day, daily for 45 days) and cyclical chemotherapy with temozolomide (150 mg/square meter of body-surface area for 5 days every 28 days). The patients were followed up clinically and with MRI. Overall survival was defined as the time between surgery and the death of the patient from disease. The maximum followup period for this cohort was 47 months. Median survival for the whole group was 16 months.
Cell Line Maintenance
The human GBM cell lines U251MG and U87MG were maintained in DMEM supplemented with 10% FBS and penicillin (100 U/ml) in a humidified atmosphere of 5% CO 2 at 37°C.
Transfection in U251MG Cell Lines and Generation of Stable Transfectants
Lipofectamine-2000-mediated transfection with 29-mer shRNA cassette directed against IGFBP-3 and vector carrying the scrambled shRNA insert was performed following the manufacturer's protocol. The sequence of the HuSH 29-mer oligonucleotide shRNA of IGFBP-3 insert is GGCTTCTGCTGGTGTGTGGATAAGTATGG. After transfection and incubation for 6 hours, the cells were cultured in DMEM supplemented with 10% FBS. Subsequently, the transfected cells were maintained in the growth medium with 100 ng/ml puromycin to generate stable transfectants. Each colony was trypsinized individually using cloning cylinders to avoid any mixup of clonal populations. Two such IGFBP-3 knockdown clones, designated Clone A and Clone B, along with vector control cells were collected and subcultured in a low concentration of puromycin. These cells were subsequently subjected to immunoblot analysis and cell proliferation, migration, and invasion assays.
Treatment of Cells With IGFBP-3 Protein
The malignant glioma cell lines (U251MG and U87MG) were treated exogenously with 400 ng/ml of rIGFBP-3 protein in the DMEM, and the cells were incubated at 37°C in 5% CO 2 atmosphere for 24 hours. Afterward, protein lysates were prepared from the cells and subjected to immunoblot analysis.
Immunoblot Analysis
Expression of IGFBP-3 and STAT-1 was analyzed by immunoblot analysis in IGFBP-3 knockdown clones and vector control cells. The effect of exogenous rIGFBP-3 protein treatment on the expression of STAT-1 was also studied by immunoblot on U251MG and U87MG cell lines. Equal amounts (50 mg) of protein from cells were resolved by 12% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis). Proteins were probed with anti-IGFBP-3 antibody (1:1000 dilution), anti-STAT-1 antibody (1:1000). b-actin levels, identified with anti-b-actin antibody (1:2000) , served as a normalizing control. Following incubation with an HRP-conjugated secondary antibody (1:2000 dilution), proteins were visualized with a chemiluminescence detection system using the SuperSignal West Femto Maximum Sensitivity Substrate (Pierce) and were subsequently captured on a radiograph.
MTT Cell Proliferation Analysis
To study cell proliferation, an MTT assay was performed. 36 Briefly, cells were plated in triplicate into 96-well plates at 5 × 10 3 cells per well and cultured in 200 μl DMEM supplemented with 10% FBS at 37°C in 5% CO 2 for 24 and 48 hours. Afterward, 20 μl of MTT reagent was added, and the cells were incubated at 37°C for 3 hours. Subsequently, DMEM was removed, and the tetrazolium crystals were dissolved in 200 μl of dimethyl sulfoxide and measured at 595 nm. The difference in absorbance between the vector control cells and the IGFBP-3 knockdown clones was calculated to derive the percentage of arrest in cell proliferation.
In Vitro Cell Migration Assay
The role of IGFBP-3 in cell motility and migration was studied using a scratch-wound healing assay. Confluent monolayer cells were scraped using a micropipette tip to generate a scratch wound and were incubated in DMEM with 10% FBS. A series of time frames (6, 12 , and 24 hours) of migration pattern at the wound edge were monitored with phase-contrast microscopy using a Leica inverted fluorescence microscope. The images were captured using the Leica Application Suite v3.1.0. At 24 hours, cell numbers were counted from both of the dishes containing IGFBP-3 knockdown clones and vector control cells. The total cell number from the control wells was used as the control to determine the percentage of inhibition of cell migration in the IGFBP-3 knockdown clones.
Matrigel Invasion Assay
The in vitro invasion assay was done using a Cell Invasion Assay kit according to the manufacturer's protocol (Chemicon). In brief, after rehydration of the inserts, IGFBP-3 knockdown cells and vector control cells were plated in the individual inserts at 10 5 cells/500 ml in serum-free DMEM. Serum-containing DMEM, which served as a chemoattractant, was added to the lower chamber. After incubation for 24 hours at 37°C in 5% CO 2 , noninvading cells from the interior of the inserts were removed. Adherent invaded cells beneath the chamber were stained with cell stain solution for 20 minutes, and the mean number of cells per chamber was calculated. The cell count of the vector control cells was considered as 100% invasion. The percentage reduction in the invasion capacity of the knockdown cells is depicted as the invasion index.
Real-Time Quantitative Polymerase Chain Reaction (qPCR) Assay
Real-time qPCR was performed on a subset of GBM (n = 73) and control (n = 10) tissue samples. Total RNA was isolated from tissues using TRI reagent (Sigma-Aldrich) per the manufacturer's protocol. Following evaluation of RNA integrity, cDNA was generated from total RNA derived from different tissue samples using the cDNA synthesis kit (Applied Biosystems). Subsequently, real-time qPCR was performed in a ViiA 7 Real-Time PCR system (Applied Biosystems) with the cDNA as template (equivalent to 10 ng of RNA) and gene-specific primer sets for STAT-1 (forward primer = TGGT GAAATTGCAAGAGCTG, reverse primer = AGACT GCCATTGGTGGACTC) using the DyNAmo HS SYBR Green qPCR kit (Thermo Scientific). All measurements were made in duplicate. For normalization, the mean expression levels of ribosomal protein L35a (RP-L35a) were used as internal controls.
Histopathology and Immunohistochemistry (IHC)
Sections of tumor tissues were examined with light microscopy, and the diagnosis of GBM was confirmed. 29, 30 Immunohistochemistry for STAT-1 was performed on 136 GBM and 30 control tissues. Antigen retrieval was done by heat treatment at 700 W in Tris-EDTA buffer (pH 9). After the initial processing steps, sections were incubated overnight with primary antibody at 4°C (dilution 1:100), followed by incubation with secondary antibody (QD440-XAK, Biogenex), and the reaction was visualized using 3,3′-diaminobenzidine (Sigma-Aldrich) as a chromogenic substrate. A negative control slide in which the primary antibody had been excluded was incorporated with each batch of staining. A visual semiquantitative grading scale was applied to assess the intensity of the immunoreactivity in a manner similar to that in our ear-lier study on IGFBP isoforms. 46 The assessment was as follows: 0 if staining was absent, 1+ if it was weak, and 2+ if it was strong. Only 2+ staining intensity was considered for analysis. The labeling index (LI) was expressed as a percentage of cells that showed 2+ positive staining among the total number of cells that were counted.
Statistical Analyses
For In Vitro Experiments. Data were analyzed using the statistical software GraphPad Prism 5 for in vitro data analysis, and the results were expressed as the mean ± standard deviation. The SPSS 15.0 statistical software was used for clinical data analysis, and the results were expressed as the median (mean ± standard deviation). A p value < 0.05 was considered significant, and all exact 2-sided p values were reported.
For Comparison of mRNA and Protein Expression of STAT-1 Between GBM and Control
Tissues. All continuous variables were tested for normal distribution and were found to be nonnormal. To compare the difference in expression of STAT-1 (mRNA and protein) between GBM and control tissue, a nonparametric Mann-Whitney test was used.
For Correlation of STAT-1 and IGFBP-3 Protein Expression With Survival in Patients With
Newly Diagnosed GBM. Expression of STAT-1 and IGFBP-3 protein was correlated with survival in this patient cohort. Since the other clinical factors like the extent of resection and postoperative KPS score were standardized per the inclusion criteria, the only clinical variable included for analysis was patient age. The significance of continuous variables was assessed using univariate Cox regression models. The variables that were significant on univariate analysis (p ≤ 0.1) were subjected to multivariate analysis. Results were reported using the p value and estimated hazard ratio along with the 95% confidence intervals. A p value < 0.05 was considered significant, and all exact 2-sided p values were reported. Furthermore, yearly survival probabilities, with the presence or absence of STAT-I expression, were calculated among patients with newly diagnosed GBM by using the Kaplan-Meier life table method.
Results

Immunoblot and Effect of IGFBP-3 Knockdown on GBM Tumor Cell Proliferation Analysis
To gain insight into the functional significance of IGFBP-3 expression in vitro, stable transfectants of IGFBP-3 knockdown clones and vector control cells were generated using a gene knockdown approach in U251MG cells. As shown in (Fig. 1A) , the knockdown of IGFBP-3 expression in both of the clones (Clones A and B) was evident on immunoblot analysis. To determine the effect of IGFBP-3 on cell proliferation, an MTT assay was performed using IGFBP-3 knockdown clones and vector control cells. Knockdown of IGFBP-3 expression resulted in significantly lower cell viability of approximately 50% compared with vector control cells. At 24 hours, the median (mean ± SD) optical density (OD) for the knockdown Clones A and B were 0.3115 (0.3123 ± 0.0142) and 0.2985 (0.3038 ± 0.0190), respectively. The difference in the OD ratios between the knockdown clones and the vector controls (0.6475 [0.6760 ± 0.0730]) was statistically significant (p < 0.0001; Fig. 1B) .
Effect of IGFBP-3 Knockdown on GBM Tumor Cell Migration
To evaluate the effect of IGFBP-3 on cell motility and migration, a scratch-wound healing assay was performed using IGFBP-3 knockdown clones and vector control cells. A series of time frames (6, 12, and 24 hours) of migration pattern at the wound edge were monitored using phase-contrast microscopy. Cell numbers from three separate image fields were counted within the gap area at 24 hours. The average cell number (500 ± 10 cells) in the vector control cells was set as 100%, and the IGFBP-3 knockdown Clones A (30 ± 10 cells) and B (20 ± 10 cells) were approximately 6.0% ± 2% and 4.0% ± 2%, respectively, of the control cells (Fig. 1C) . This suggests that decreasing IGFBP-3 expression significantly impairs the motility and migration capacity (> 95%) of U251MG cells in vitro.
Effect of IGFBP-3 Knockdown on GBM Tumor Cell Invasion in Vitro
To investigate if IGFBP-3 influences GBM tumor cell invasion, we performed the Matrigel invasion assay by using IGFBP-3 knockdown clones and vector control cells. Our results showed that decreasing IGFBP-3 gene expression significantly impairs the invasive capacity of U251MG cells in vitro by more than 80% compared with vector control cells (Fig. 1D) .
IGFBP-3 Regulates the Expression of STAT-1 in Malignant Glioma Cells
In a previous report, STAT-1 regulation by IGFBP-3 in the context of early chondrogenesis was demonstrated. 49 Moreover, the role of STAT-1 in the pathogenesis of other cancers has been well established. 1, 14, 18, 22, 28, 47, 50 Since our previous studies have suggested protumorigenic actions of IGFBP-3 in GBM, it is possible that this action may involve STAT-1 regulation. To test this hypothesis, IGFBP-3 knockdown clones and vector control cells were analyzed for STAT-1 protein expression by immunoblot analysis. As shown in Fig. 2A , IGFBP-3 knockdown clones had significantly reduced STAT-1 protein expression. Additionally, immunoblot analysis demonstrated that the exogenous addition of rIGFBP-3 protein increased the levels of STAT-1 protein in U251MG and U87MG cells (Fig. 2B and C) , in comparison with levels in the untreated cells. These experiments confirmed our hypothesis that IGFBP-3 regulates STAT-1 expression in malignant glioma cells.
mRNA and Protein Expression Pattern of STAT-1 in GBM and Control Tissues
In view of the influence of IGFBP-3 on STAT-1 expression in glioma cell lines, we studied the mRNA and protein expression pattern of STAT-1 in human GBM and control samples by using real-time qPCR and IHC. The median (mean ± SD) log2 ratio of STAT-1 mRNA expression was 0.03663 (0.0004 ± 0.5722) in control tissues and 0.8533 (0.9551 ± 2.017) in GBM tissues.
The mRNA expression of STAT-1 demonstrated statistically significant (p = 0.0239) overexpression in GBM tissues, as compared with controls, with a median fold change (log2) of 0.853 on the Mann-Whitney test (Fig. 3  upper) .
For STAT-1 protein expression according to IHC, we considered only cytoplasmic staining for analysis, which is in line with a previous report. 20 The median (mean ± SD) LI for STAT-1 cytoplasmic expression in GBM was 15.00 (14.92 ± 13.85); in controls, 0.00 (0.00 ± 0.00). The difference in STAT-1 protein expression between GBM and control tissues was statistically significant (p < 0.001; Fig. 3 lower) .
Representative micrographs of STAT-1 protein expression in control and GBM tissues are shown in Fig. 4 . Control brain tissue sections stained negatively (Fig. 4A) . In GBMs, staining was predominantly confined to the cytoplasm of neoplastic astrocytes. In approximately twothirds of the cases, concomitant nuclear staining was also observed. Heterogeneity of staining was noted within individual tumor samples ( Fig. 4B and C) . Large atypical tumor astrocytes, tumor giant cells (Fig. 4B ), perivascular cells (Fig. 4D) , and cells infiltrating the adjacent cortex showed strong staining.
Effect of STAT-1 and IGFBP-3 Protein Expression on Survival in Patients With Newly Diagnosed GBM
We then studied the effect of STAT-1 and IGFBP-3 protein expression on the prognosis of newly diagnosed GBM. Univariate Cox regression models revealed that STAT-1 protein expression (HR 1.017, p = 0.013, 95% CI 1.004-1.031) and patient age (HR 1.026, p = 0.002, 95% CI 1.009-1.043) were associated with shorter survival in this prospective cohort of patients with GBM; however, IGFBP-3 expression did not significantly correlate with survival (HR 1.013, p = 0.118, 95% CI 0.997-1.029; Table  1 ). For clinical significance, a cutoff of 10% STAT-1 LI was considered to indicate a tumor as positively stained. The median survival of patients with tumors negative for STAT-1 was 21 months (95% CI 13.6-28.4 months), whereas that of patients with STAT-1-positive tumors was 13 months (95% CI 11.2-14.8 months), with the difference being statistically significant (p = 0.008; Fig. 5 ).
The variables of patient age and STAT-1 LI were associated with survival on univariate analysis at the predetermined significance level of 0.1 and were therefore included in the multivariate Cox model. On performing the multivariate Cox regression analysis, it was observed that patient age (HR 1.025, p = 0.005, 95% CI 1.008-1.042) and STAT-1 protein expression (HR 1.015, p = 0.033, 95% CI 1.001-1.029) were independent predictors of a poor outcome in GBM patients (Table 1) .
We also noted that STAT-1 expression had an influence on the long-term survival of GBM patients. The 3-year survival rate was only 12% in patients with STAT-1 overexpression compared with 30% in patients with negative STAT-1 expression.
Discussion
The results of our previous study showed that IGFBP-3 is an adverse prognostic biomarker in GBM patients. 46 In the present study, the influence of IGFBP-3 expression on GBM tumor cell proliferation, migration, and invasion was analyzed in human U251MG cells in vitro by using a shRNA-based gene knockdown approach. A concomitant reduction of nearly 50% in cell proliferation and more than 95% in cell motility and migration capac- ity observed following IGFBP-3 knockdown strengthens its hypothetical role in GBM pathogenesis and progression. Moreover, the invasive capacity of the IGFBP-3 knockdown clones was markedly reduced by more than 80%, compared with vector control cells, reflecting the influence of IGFBP-3 on the invasive capability of GBM cells. Interestingly, IGFBP-3 has been shown to possess a bidirectional role in tumor behavior: proapoptotic/antiproliferative or growth stimulatory. 19, 37, 42, 53 Our findings accord with those in a previous study showing the growthstimulatory effects of IGFBP-3 in MCF-10A mammary epithelial cells. 34 The involvement of IGFBP-3 in migration and invasion are less well documented. Similar to our findings, which showed that IGFBP-3 is involved in malignant glioma cell motility and migration, an earlier report has shown that IGFBP-3 is essential for the migration of melanoma cells. 59 On the contrary, some studies have shown IGFBP-3 significantly reduces the migration of PC3 prostate cancer cells, Ewing's sarcoma cells, and non-small cell lung cancers, further emphasizing the multifunctional roles of IGFBP-3 in different human cancers. 4, 35, 38 Our results demonstrating IGFBP-3's involvement in GBM tumor cell invasion in vitro are also consistent with the findings of previous studies on malignant melanoma and esophageal squamous cell carcinoma.
37,59
In contrast, other studies on ovarian, prostate, and lung carcinomas have demonstrated that IGFBP-3 inhibits cell invasion in vitro. 4, 35, 38, 53 Taken together, IGFBP-3 actions in tumorigenesis are context dependent.
IGFBP-3 could play a role in GBM pathogenesis that could be performed through several potential mecha- nisms. It could exert its action through an IGF-dependent pathway, recruiting IGF-1 and IGF-2 to the tumor microenvironment, or through an IGF-independent pathway via molecules such as TGFb, as recently demonstrated in breast cancers. 17, 25 A literature search for similar such molecules yielded an interesting one, STAT-1, which is regulated by IGFBP-3 during early chondrogenesis.
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There are 7 STAT proteins, and among these, STAT-1 is known to be activated not only by cytokines but also by growth factors, such as epidermal growth factor, platelet-derived growth factor, insulin, and IGF-1.
5,39 STAT-1 expression has been described in various malignancies including leukemia, renal cell carcinoma, head and neck tumors, breast cancer, and melanoma. 1, 14, 18, 22, 28, 47, 50 STAT-1 has also been reported to promote tumor aggressiveness by rendering the cells resistant to ionizing radiation. 11, 26, 27 In the present study, we showed that IGFBP-3 regulates the expression of STAT-1 in malignant glioma cells (U251MG and U87MG cells) when treated with rIGFBP-3 protein.
Further, the suppression of STAT-1 expression was unequivocally established by knockdown of IGFBP-3. These data suggest a functional role for STAT-1 in IGFBP-3-mediated protumorigenic actions.
After establishing the regulation of STAT-1 by IGFBP-3 through in vitro experiments, we demonstrated the overexpression of STAT-1 mRNA and protein in GBM as compared with levels in control tissues. While no studies have detailed the mRNA expression of STAT-1 in GBM tissues, a report on a small set of GBM samples has revealed increased protein expression of STAT-1 in about 48% of tumors. 20 In our study we noted positive staining in 61% of tumors via IHC. STAT-1 staining was heterogeneous in GBM tissues. Even though the staining was predominantly confined to the cytoplasm of neoplastic astrocytes, in about two-thirds of the cases, we noted concomitant nuclear staining. This finding contrasts with that in a previous study, in which the authors observed only cytoplasmic staining, which was attributed to a probable inactivation of protein leading to the immune escape of tumor cells. 20 Interestingly, the tumor cells in the perivascular region and those infiltrating the adjacent cortex were intensely labeled, indicating a role for STAT-1 in tumor cell invasion.
We then assessed the influence of STAT-1 protein expression on the prognosis of GBM and noted that STAT-1 was significantly associated with shorter survival according to univariate Cox regression and Kaplan-Meier analyses.
A multivariate Cox proportional hazards model showed that STAT-1 expression and patient age were independently associated with a worse clinical outcome in GBM patients. In our earlier study IGFBP-3 protein expression showed a survival correlation in GBM patients; 46 however, extended follow-up of the same patient cohort revealed that IGFBP-3 lost its prognostic significance, while STAT-1 expression and patient age were associated with shorter patient survival. Although we have demonstrated that IGFBP-3 regulates STAT-1 expression in glioma cells, it is also likely that other molecules can regulate STAT-1, placing STAT-1, as compared with IGFBP-3, as a key molecule influencing the survival of GBM patients with a longer follow-up. In support of this hypothesis, we have also shown that STAT-1 expression had an influence on the long-term survival rates of GBM patients. The 3-year survival rate was only 12% in patients with tumors positive for STAT-1, as compared with 30% in patients with tumors negative for STAT-1.
Taken together, our observations support the contention that STAT-1 expression has a significant influence on the survival of GBM patients. There is only one report that has shown that the expression of IFN/STAT-1 signaling genes predicts a poor survival outcome in the proneural subgroup of GBM patients. Authors of that report hypothesized that the poor prognosis could be attributable to the chemoresistance and/or radiation resistance of tumors that express STAT-1. 10 Work on other tumors and cell lines has shown that, like IGFBP-3, STAT-1 also has a dual role in cancer. For example, the overexpression of STAT-1 has been associated with a better outcome in squamous cell carcinoma and mammary cancers. 2, 57, 58 Interestingly, contrary to our observations, a recent study has shown the decreased expression of STAT-1 protein in GBMs. 24 Authors of that study also observed that transfection of the U87MG cells with STAT-1 plasmid in vitro significantly inhibited cell growth and increased apoptotic cell death, and thus they attributed a antitumorigenic role to STAT-1. Another study points toward a protumorigenic role of STAT-1 in GBM. 10 These contradictory reports of STAT-1 in GBM make it an interesting molecule for further detailed analysis.
Conclusions
In summary, the present study highlights the critical role of IGFBP-3 in GBM pathogenesis and progression by facilitating tumor cell proliferation, invasion, and migration. IGFBP-3 regulates STAT-1 in malignant glioma cells, and STAT-1 is overexpressed in GBM tissues. Further, STAT-1 has been identified as a molecule strongly associated with a poor prognosis in GBM, with an incompletely understood biological role, and thus making it an interesting molecule for further exploration. 
